1 |
Han SK, Choi KJ, Kim WK: Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers: a pilot study. Plast Reconstr Surg 114: 1783, 2003
DOI
ScienceOn
|
2 |
Cavallini M: Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Repair Regen 15: 35, 2007
DOI
ScienceOn
|
3 |
Brown TJ, Lioubin MN, Marquardt H: Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 139: 2977, 1987
|
4 |
Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635, 1996
DOI
ScienceOn
|
5 |
Goren I, Kampfer H, Muller E, Schiefelbein D, Pfeilschifter J, Frank S: Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: Implications for normal and diabetes-impaired wounds. J Invest Dermatol 126: 628, 2006
DOI
ScienceOn
|
6 |
Broughton G 2nd, Janis JE, Attinger CE: Wound healing: an overview. Plast Reconstr Surg 117(7 Suppl): 1e-S, 2006
DOI
ScienceOn
|
7 |
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1, 2003
DOI
ScienceOn
|
8 |
Scaffidi AK, Mutsaers SE, Moodley YP, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA: Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 136: 793, 2002
DOI
ScienceOn
|
9 |
Hibi M, Nakajima K, Hirano T: IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med 74: 1, 1996
DOI
|
10 |
Ihn H, Tamaki K: Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Immunol 165: 2149, 2000
DOI
|
11 |
Wallace PM, Macmaster JF, Rillema JR, Rouleau KA, Hanson MB, Burstein SA, Shoyab M: In vivo properties of oncostatin M. Ann N Y Acad Sci 762: 42, 1995
|
12 |
Hehenberger K, Kratz G, Hansson A, Brismar K: Fibroblasts derived from human chronic diabetic wounds have a decreased proliferation rate, which is recovered by the addition of heparin. J Dermatol Sci 16: 144, 1998
DOI
ScienceOn
|
13 |
Richards CD, Shoyab M, Brown TJ, Gauldie J: Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 150: 5596, 1993
|
14 |
Wallace PM, Macmaster JF, Rouleau KA, Brown TJ, Loy JK, Donaldson KL, Wahl AF: Regulation of inflammatory responses by oncostatin M. J Immunol 162: 5547, 1999
|
15 |
Chun KW, Han SK, Lee BI, Kim WK: Optimal concentration of OSM for wound healing activity of fibroblasts. J Korea Wound Care Soc 2: 77, 2006
|